Guidelines For Insulin Initiation and Adjustment In Primary Care

More documents

Recommendations

Info

Guidelines For Insulin Adjustment In Primary Care Appendix 4 Scottish Medicines Consortium Insulin glargine (Lantus®) (No. 11/02) Aventis Summary of Recommendation 4 October 2002 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows: ADVICE Recommended for restricted use within the NHS Scotland. REASONS FOR ADVICE Insulin glargine is an acceptable treatment for patients with diabetes mellitus. Pending further studies, its use should be targeted on patients who are at risk or experience unacceptable frequency and/or severity of nocturnal hypoglycaemia on attempting to achieve better hypoglycaemic control during treatment with established insulins. It is also acceptable as a once daily insulin therapy for patients who require carer administration of their insulin. At present the evidence does not support its routine use in patients with type 2 diabetes unless they suffer from recurrent episodes of hypoglycemia or require assistance with their insulin injections. Professor David H Lawson Chairman Secretariat - Delta House 50 West Nile Street Glasgow G1 2NP Telephone 0141 225 6997 Fax 0141 248 3778 E-mail jmitchell@htbs.org.uk Chairman Professor David Lawson Reviewed January 2010 31
Guidelines For Insulin Adjustment In Primary Care Appendix 4 Scottish Medicines Consortium insulin glargine 100 units/ml solution for injection in a prefilled pen (Lantus® SoloStar®) (No: 456/08) Sanofi-aventis Product Update 07 March 2008 The Scottish Medicines Consortium has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following an abbreviated submission insulin glargine 100 units/ml solution for injection in a pre-filled pen (Lantus SoloStar ) is accepted for restricted use in the treatment of adults, adolescents and children of 6 years or above with diabetes mellitus, where treatment with insulin is required. It may be used in patients in whom treatment with this insulin analogue is appropriate and in whom the use of a pre-filled pen offers advantages over a pen and cartridge device. The use of insulin glargine should be targeted on patients with Type I diabetes who are at risk of or experience unacceptable frequency and/or severity of nocturnal hypoglycaemia on attempting to achieve better hypoglycaemic control during treatment with established insulin’s. It is also acceptable as a once daily insulin therapy for patients who require carer administration of their insulin. In patients with type 2 diabetes, it should be restricted to those who suffer from recurrent episodes of hypoglycemia or require assistance with their insulin injections. Advice context: No part of this advice may be used without the whole of the advice being quoted in full. This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer. This assessment is based on data submitted by the applicant company up to and including 16th January 2008. Chairman, Scottish Medicines Consortium Reviewed January 2010 Secretariat - Delta House 50 West Nile Street Glasgow G1 2NP Telephone 0141 225 6989 E-mail: rosie.murray@nhs.net Chairman Professor David Webb 32
Page 1 and 2: Guidelines for Insulin Initiation a
Page 3 and 4: Table of Contents Guidelines For In
Page 5 and 6: Guidelines For Insulin Adjustment I
Page 7 and 8: Table A Guidelines For Insulin Adju
Page 17 and 18: INSULIN CONVERSION / EDUCATION CHEC
Page 27 and 28: Appendix 1 Guidelines For Insulin A
Page 29 and 30: Appendix 2 Guidelines For Insulin A
Page 31: Appendix 3 Guidelines For Insulin A
Page 35 and 36: Eli Lilly; www.lilly.co.uk 01256 31
Page 37: References: Reviewed January 2010 G

Guidelines For Insulin Initiation and Adjustment In Primary Care

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?